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Nicotine-Induced Neuroprotection in Drosophila Models of Parkinson's Disease 
Abstract 
Parkinson's disease (PD) causes rigidity, tremors, and posture impairments. There is no 
cure for this disease and its symptoms intensify with age. In this study, fruit flies were 
induced with PD using rotenone and the flies in treatment group were provided with food 
that contained nicotine to determine if nicotine causes neuroprotection and alleviates 
symptoms of PD. A climbing assay was used to assess the severity of symptoms of PD in 
the control and experimental groups. The PD induced flies that received nicotine did not 
show a significant difference in motor ability and therefore did not experience 
neuroprotection. 
1. Introduction 
Parkinson's disease is a neurodegenerative disease that destroys the dopaminergic 
neurons in the substantia nigra of the brain. It also causes a decrease in the level of 
dopamine in the striatum (Lei et al., 2009). Physical symptoms include rigidity, tremors, 
and posture impairments (Quick et al., 2007). The symptoms of PD intensify with age and 
the disease has no known cure. There are medications that help alleviate the symptoms of 
PD, but they do not prevent or treat the condition and they have adverse side effects. This 
is why it is critical to try to find a drug that can cause neuroprotection for PD patients (Lei 
et al., 2009). 
It is important to study neuroprotection and neurodegeneration on living organisms 
because their complex processes can affect outcomes of treatments. Drosophila, known 
more commonly as the fruit fly, is a useful model organism because it has, a very short 
generation time and it is easy to manipulate its environment to test different variables. 
Fruit flies are similar to humans in that they can carry out complex behaviors (Botella et al., 
2009). 
In a study by Trinh et al. (2010), the climbing index of PD induced fruit flies was 
calculated after the flies consumed tobacco-free food, cornmeal molasses or food 
containing tobacco. The flies in the experimental group experienced neuroprotection and 
an increased climbing index. In addition, flies in the experimental group experienced an 
increased lifespan from 45 days to 65 days. Flies in the control group did not experience an 
increased climbing index or neuroprotection and had a lifespan of 40 days (Trinh et al., 
2010). 
Other studies have sought to determine if nicotine is the ingredient in the tobacco 
that causes the protective effect. In a study by Lei et al. (2009), mice were induced with PD 
using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Mice in the experimental 
group were injected with nicotine and subsequently scored higher on behavioral tests, and 
experienced restoration of their degenerated neurons (Lei et al., 2009). 
A study by Morens et al. (1995) found that the risk of PD decreases about 50% in 
smokers. Nicotine was suspected to be the compound causing this result because it 
increases striatal dopamine release (Dani eta!., 2006). It also protects the brain from 
degeneration due to toxic insults in different experimental designs (O'neill eta!., 2002). 
Nicotine was used to test against nigrostriatal damage in nonhuman primates (Quik eta!., 
2007). The experiments were designed to mimic long-term smoking in humans. This was 
achieved through nicotine exposure in drinking water for a year on primates that were 
induced with slow nigrostriatal damage over the previous six months using MPTP. It was 
shown that striatal markers linked to dopamine were more abundant in nicotine-treated 
monkeys compared to monkeys not receiving nicotine treatments. Not only did the 
nicotine treatment improve molecular measures of dopamine levels it also normalized the 
abnormal activity of the dopamine pathways. These finding support the idea that nicotine 
is one of the key ingredients in tobacco that lowers the risk of PD in smokers (Quik eta!., 
2007). 
Nicotine has been shown to help improve motor activity in people with PD. When 
15 patients with early to moderate PD were administered nicotine intravenously and 
through a patch, their motor activity improved by several measures (Kelton eta!., 2000). 
This result corroborates findings that PD-related tremors and rigidity decrease due to 
smoking (Quik and Kulak, 2002). It has been reported multiple times that tobacco users 
have a 20-80% decreased risk of developing PD when compared to people who do not use 
tobacco (Balfour eta!., 1996; Baron, 1996; Haack eta!., 1981;Morens eta!., 1995). The 
responsible compound in tobacco has yet to be discovered. One hypothesis for the 
mechanism of action is that tobacco products reduce enzymatic activity. Additionally, 
nicotine receptor activation stimulates dopamine release. This accelerates neural firing 
and helps the brain function more efficiently (Quik and Kulak, 2002). 
Some studies have suggested that there is no correlation between using tobacco 
products and a decreased risk of developing PD. A study by Kandinov eta!. (2007) 
observed patients diagnosed with PD from Tel Aviv Sourasky Medical Center. It was found 
that there was no correlation between patient's use of cigarettes and the rate of 
progression of PD. The authors' findings were limited in that tobacco use was specific to 
smoking cigarettes (Kandinov eta!., 2007). 
The central focus of my thesis is to determine whether or not nicotine causes a 
neuroprotective effect in Drosophila models of PD. I hypothesize that nicotine is the main 
ingredient in tobacco that causes a neuroprotective effect, which may result in a slower 
progression of PD. 
2. Materials and methods 
2.1 Preparation of Flies 
To conduct this experiment, 100 Drosophila were used. The flies were sexed and 
only the males were used for this study to reduce variability in behaviors and prevent new 
offspring from being produced. Twenty flies were placed in each of two vials and were 
provided with 8.9 f.LL (.5 nM) of nicotine, 10 mL of 5% sucrose, and 1% agar food. The 
remaining sixty flies were provided with food that lacked nicotine. They were housed in 
three vials and provided with 10 mL of 5% sucrose and 1 o/o agar food. Both the control and 
experimental flies were given time to consume their food for a period of seven days. 
After seven days had passed, the sixty flies in the control group were transported 
into three different vials of twenty flies. Flies in two of the three vials were induced with 
PD using different concentrations of rotenone. One group of twenty flies was provided 
with food containing 10 mL of 5% sucrose and 1 o/o agar. The other two groups of 20 flies 
were provided with either 30 mM or 40 mM of rotenone (one concentration per group) in 
their food containing 10mL of 5% sucrose and 1 o/o agar. 
The 40 flies that had been exposed to nicotine were divided into two different 
groups after the seven days had past. All of the flies in this group were induced with PD 
using rotenone. Each of the flies was provided with either 30 mM or 40 mM of rotenone 
(one concentration per group) and provided with 10 mL of 5% sucrose and 1 o/o agar food. 
2.2 Climbing Assay 
After seven days, the climbing index of all flies was measured. The climbing 
chambers were made by taping two clear plastic vials together vertically. A height of 8 em 
was measured and marked around the circumference of the tube. Five climbing chambers 
were made for each treatment group. The flies were transported into their climbing 
chambers and were given a minute to acclimate prior to the assay. 
To perform the assay, the bottom of the tube was tapped to stimulate climbing and a 
timer was started. After 10 seconds the flies that successfully completed the Scm climb 
were counted. All of the flies were tested simultaneously starting with the control group. 
Control and experimental groups were tested sequentially to allow time for rest and 
recovery of flies between the ten trials that were conducted per group. The number of flies 
that were successful per trial was recorded as a percentage of total flies per treatment 
group. 
3. Results 
The flies treated with 30 mM of rotenone exhibited a lower climbing ability in the 
assay compared to the control flies. However the difference was not statistically significant 
using an alpha of0.05 (p= 0.054). The flies treated with 40 mM of rotenone were more 
adept at climbing than the flies treated with 30mM of rotenone, but again the difference 
was not significant (p=0.708). 
The flies treated with 0.5 nM of nicotine plus 30 mM of rotenone had a greater 
climbing ability compared to the flies treated with 30 mM of rotenone alone, but the 
difference was not significant (p=0.708). The flies treated with 0.5 nM of nicotine plus 40 
mM rotenone had the lowest climbing ability of all of the treatment conditions. 
30mM 
Rotenone 40 mM Rotenone 
Trial 30mM 40mM plus 0.5nM plus 0.5 nM 
Number Control Rotenone Rotenone Nicotine Nicotine 
1 0.6 0.67 0.58 0.2 0.21 
2 0.4 0.33 0.66 0.6 0.28 
3 0.5 0.22 0.33 0.4 0.42 
4 0.6 0.22 0.33 0.4 0.21 
5 0.3 0.33 0.58 0.5 0.29 
6 0.2 0.22 0.33 0.3 0.21 
7 0.5 0.33 0.41 0.4 0.14 
8 0.5 0.44 0.25 0.3 0.21 
9 0.4 0.22 0.25 0.4 0.14 
10 0.4 0 0.42 0.4 0.07 
Mean 0.44 0.3 0.42 0.39 0.22 
Fig. 1. The proportion of flies that successfully climbed Scm in 10 seconds and the mean 















Control 3o mM Rotenone40 mM Rotenone 30mM 40mM 
Rotenone .5 nM Rotenone .5 nM 
Nicotine Nicotine 
Fig. 2. The effects of rotenone and nicotine on the climbing success of flies. The treatment 
conditions are shown on the x-axis, and the proportion of successful flies able to climb 8 em 
in 10 seconds is shown on they-axis. 
30mM 40mM 
Rotenone Rotenone 
3omM 40mM .SnM .SnM 
Control Rotenone Rotenone Nicotine Nicotine 
0.44 0.5 0.43 0.44 0.36 
Fig. 3. The proportion of flies that died prior to the climbing assay. 
4. Discussion 
There was evidence of a lower climbing ability of flies treated with rotenone 
compared to the control flies, although the difference between the groups was not 
significant. Adding a 35 mM concentration of rotenone to help the PD modeL Using a larger 
number of flies in each treatment group should also be attempted. Using young adult flies 
may decrease the number of deaths during the experiment. 
There are many other methods that could be used to induce PD in flies besides 
rotenone. To study the function and contribution of genes involved in PD, mutational 
analysis, genetic screens and RNAi technology could be used (Botella eta!., 2009). Many 
genes that are involved in PD have counterparts in flies, but others may be absent. The 
gene a-synuclein has been linked to PD and has a mechanism of toxicity that needs 
investigation, but this gene is not present in flies. To incorporate this gene into flies, the 
human-related transgene is cloned into a plasmid. This plasmid contains the 'upstream 
activating sequence' that serves as a target for GAL4, a transcription activator. If the fly had 
GAL4 present then it could express this gene and thus been used as a model of PD (Botella 
eta!., 2009). 
The flies treated with 30 mM of rotenone and 0.5 nM of nicotine showed evidence of 
higher climbing abilities when compared to the flies treated with 30 mM of rotenone alone, 
although there was no significant difference between the groups. If the dosage of nicotine 
was increased, this may produce a significant difference. 
Direct observation of neuroprotection, rather than testing motor ability, would be 
useful for future studies. The brain of each fly could be dissected in 1x PBS and fixed for 30 
minutes in paraformaldahyde. After treating the brains with 10% serum and staining them 
against tyrosine hydroxylase, observations could be made under a confocal microscope to 
determine the integrity of dopamine secreting neurons (Trinh eta!., 2010). 
The fast generation time of flies helped to allow for greater numbers of individuals 
to test on, but it also allowed for a limited amount of time to test the flies. Some of the 
treatment groups experienced high mortality and this reduced the sample sizes. If a 
different model organism was used with a longer life expectancy such as rats or monkeys, 
this problem may have been avoided. However different animal models may show 
discrepancies in the neuroprotective effect of nicotine. Mice, for example are not effective 
models for testing neuroprotection due to nicotine exposure. In contrast, rats, flies and 
nonhuman primates are effective at modeling human diseases and have reproducible 
neuroprotection (Quick eta!., 2007). 
Our results did not show that nicotine causes neuroprotection in Drosophilla models 
of PD. We need to improve the induction of PO in the flies and look for evidence of 
neuroprotection in ways other than testing the climbing ability. More testing should be 
conducted in the future to see if nicotine or other compounds can cause neuroprotection 
and help reduce the progression of PO in humans. 
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